|
KMID : 0923620180180030019
|
|
Immune Network
2018 Volume.18 No. 3 p.19 ~ p.19
|
|
|
L1 Recombinant Proteins of HPV Tested for Antibody Forming Using Sera of HPV Quadrivalent Vaccine
|
|
Akuzum Begum
Kim Sin-Ae
Nguyen Tam Thanh
Hong Jea-Woo
Lee Si-Young
Kim Eun-Hye
Kim Joo-Hee
Choi Yeo-Ok
Jhun Hyun-Jhung
Lee Young-Min
Kim Hyun-Woo
Sohn Dong-Hyun
Kim Soo-Hyun
|
|
|
Abstract
|
|
|
|
Virus-like particles (VLPs) derived from human papillomavirus (HPV) L1 capsid proteins were used for HPV quadrivalent recombinant vaccine. The HPV quadrivalent vaccine is administrated in a 3-dose regimen of initial injection followed by subsequent doses at 2 and 6 months to prevent cervical cancer, vulvar, and vaginal cancers. The type 6, 11, 16, or 18 of HPV infection is associated with precancerous lesions and genital warts in adolescents and young women. The HPV vaccine is composed of viral L1 capsid proteins are produced in eukaryotic expression systems and puri?ed in the form of VLPs. Four different the L1 protein of 3 different subtypes of HPV: HPV11, HPV16, and HPV18 were expressed in Escherichia coli divided into 2 fragments as N- and C-terminal of each protein in order to examine the efficacy of HPV vaccine. Vaccinated sera failed to recognize N-terminal L1 HPV type 16 and type 18 by western blot while they detected N-terminal L1 protein of HPV type 11. Moreover, the recombinant C-terminal L1 proteins of type 16 was non-specifically recognized by the secondary antibody conjugated with horseradish peroxidase. This expression and purification system may provide simple method to obtain robust recombinant L1 protein of HPV subtypes to improve biochemical analysis of antigens with immunized sera.
|
|
|
KEYWORD
|
|
|
Papillomaviridae, L1 capsid proteins, Recombinant proteins, Enzyme-linked immunosorbent assay, Western blot
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
   
|